+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 49 Pages
  • June 2025
  • GlobalData
  • Vaxart Inc
  • ID: 4432328
Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vaxart Inc (Vaxart) is a clinical-stage biotechnology company which focuses on developing oral recombinant vaccines. The company's main activities involve the research and development of vaccine candidates using its proprietary Vector-Adjuvant-Antigen Standardized Technology (VAAST) platform. Vaxart is developing prophylactic vaccine candidates for a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. It is also developing a therapeutic immune-oncology vaccine, which targets cervical cancer and dysplasia caused by human papilloma virus (HPV). Vaxart is headquartered in San Francisco, California, the US.

Vaxart Inc Key Recent Developments

  • May 29, 2025: Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders
  • May 13, 2025: Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results
  • May 13, 2025: Vaxart Appoints Jeroen Grasman as Chief Financial Officer
  • Mar 20, 2025: Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Vaxart Inc - Key Facts
  • Vaxart Inc - Key Employees
  • Vaxart Inc - Key Employee Biographies
  • Vaxart Inc - Major Products and Services
  • Vaxart Inc - History
  • Vaxart Inc - Company Statement
  • Vaxart Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Vaxart Inc - Business Description
  • R&D Overview
  • Vaxart Inc - Corporate Strategy
  • Vaxart Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Vaxart Inc - Strengths
  • Vaxart Inc - Weaknesses
  • Vaxart Inc - Opportunities
  • Vaxart Inc - Threats
  • Vaxart Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Vaxart Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 29, 2025: Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders
  • May 13, 2025: Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results
  • May 13, 2025: Vaxart Appoints Jeroen Grasman as Chief Financial Officer
  • Mar 20, 2025: Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
  • Jan 28, 2025: Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors
  • Jan 14, 2025: Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs
  • Aug 08, 2024: Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results
  • Jun 17, 2024: Vaxart Provides Business Update
  • May 07, 2024: Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13
  • Mar 14, 2024: Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Vaxart Inc, Key Facts
  • Vaxart Inc, Key Employees
  • Vaxart Inc, Key Employee Biographies
  • Vaxart Inc, Major Products and Services
  • Vaxart Inc, History
  • Vaxart Inc, Subsidiaries
  • Vaxart Inc, Key Competitors
  • Vaxart Inc, Ratios based on current share price
  • Vaxart Inc, Annual Ratios
  • Vaxart Inc, Interim Ratios
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Vaxart Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Vaxart Inc, Performance Chart (2020 - 2024)
  • Vaxart Inc, Ratio Charts
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Sinovac Biotech Ltd
  • Sanofi
  • Johnson & Johnson Innovative Medicine
  • CSL Ltd
  • Anhui Zhifei Long Kema Biological Pharmaceutical Co Ltd
  • Novartis AG
  • Genexine Inc
  • Inovio Pharmaceuticals Inc
  • HilleVax Inc
  • Medicago Inc
  • F. Hoffmann-La Roche Ltd
  • Novavax Inc
  • Pfizer Inc
  • Merck & Co Inc
  • Moderna Inc
  • Emergent BioSolutions Inc
  • Selva Therapeutics Inc
  • GSK plc
  • Ayala Pharmaceuticals Inc.